YAP1 and colonic neoplasm: This anti-hCSCs activity of Ova in CML cells is consistent with previous results obtained in solid tumors, such as in the triple negative breast cancer (TNBC), where exposure to Ova increased the sensitivity of doxorubicin -resistant TNBC cells to doxorubicin, and induced the loss of CSC-like phenotype in the TNBC cells, as demonstrated by significant dissolution and necrosis of formed mammospheres [12], as well as in colon cancer, where treatment with Ova suppressed the expression of YAP1, inhibited M2 macrophage polarization, and prevented the generation of CSC-like colonospheres [26].